Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Gewinn über Erwartungen: Primoris-Aktie stürzt vorbörslich ab (Investing.com DE) +++ PRIMORIS Aktie -4,35%

HENRY SCHEIN Aktie

 >HENRY SCHEIN Aktienkurs 
72.04 EUR    +5.4%    (TradegateBSX)
Ask: 72.98 EUR / 280 Stück
Bid: 72.62 EUR / 280 Stück
Tagesumsatz: 291 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
HENRY SCHEIN Aktie über LYNX handeln
>HENRY SCHEIN Performance
1 Woche: +2,2%
1 Monat: +3,0%
3 Monate: +8,8%
6 Monate: +13,0%
1 Jahr: -8,9%
laufendes Jahr: +3,6%
>HENRY SCHEIN Aktie
Name:  HENRY SCHEIN INC. DL-,01
Land:  USA
Sektor:  Handel
ISIN/ Wkn:  US8064071025 / 897961
Symbol/ Ticker:  HS2 (Frankfurt) / HSIC (NASDAQ)
Kürzel:  FRA:HS2, ETR:HS2, HS2:GR, NASDAQ:HSIC
Index:  S&P500
Webseite:  https://www.henryschein.c..
Profil:  Henry Schein, Inc. is a leading distributor of health care products and services, primarily catering to office-based dental, animal health, and medical practitioners. The company also serves dental la..
>Volltext..
Marktkapitalisierung:  7948.75 Mio. EUR
Unternehmenswert:  12071.81 Mio. EUR
Umsatz:  10978.64 Mio. EUR
EBITDA:  916.44 Mio. EUR
Nettogewinn:  331.79 Mio. EUR
Gewinn je Aktie:  2.71 EUR
Schulden:  2919.89 Mio. EUR
Liquide Mittel:  115.4 Mio. EUR
Operativer Cashflow:  453.98 Mio. EUR
Bargeldquote:  0.04
Umsatzwachstum:  -1.78%
Gewinnwachstum:  18.15%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  HENRY SCHEIN
Letzte Datenerhebung:  24.02.26
>HENRY SCHEIN Kennzahlen
Aktien/ Unternehmen:
Aktien: 117.73 Mio. St.
Frei handelbar: 85.13%
Rückkaufquote: 5.03%
Mitarbeiter: 25000
Umsatz/Mitarb.: 0.43 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 2.44%
Bewertung:
KGV: 24.21
KGV lG: 15.59
KUV: 0.72
KBV: 2.7
PEG-Ratio: 0.82
EV/EBITDA: 13.17
Rentabilität:
Bruttomarge: 29.2%
Gewinnmarge: 3.02%
Operative Marge: 5.99%
Managementeffizenz:
Gesamtkaprendite: 3.6%
Eigenkaprendite: 11.39%
>HENRY SCHEIN Peer Group
Handel
 
24.02.26 - 16:45
Henry Schein (HSIC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
 
The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....
24.02.26 - 16:12
Henry Schein (HSIC) Q4 2025 Earnings Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
24.02.26 - 15:31
Henry Schein übertrifft Prognosen für Q4 2025 – Aktie legt zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
24.02.26 - 15:01
Henry Schein (HSIC) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
 
Henry Schein (HSIC) delivered earnings and revenue surprises of +3.08% and +3.09%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
24.02.26 - 13:24
Henry Schein Q4 Earnings Rise (AFX)
 
MELVILLE (dpa-AFX) - Henry Schein, Inc. (HSIC), a healthcare products and solutions company, Tuesday reported higher earnings and revenue for the fourth quarter compared to the same period last ye......
24.02.26 - 12:42
Henry Schein Inc. Q4 Profit Advances (AFX)
 
MELVILLE (dpa-AFX) - Henry Schein Inc. (HSIC) released earnings for its fourth quarter that Increases, from last yearThe company's bottom line came in at $101 million, or $0.85 per share. This com......
24.02.26 - 12:30
Earnings Breakdown: Henry Schein Q4 (Benzinga)
 
Importance Rank:  1 read more...
24.02.26 - 12:06
Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance (Business Wire)
 
Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. “Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particularly our global equipment, specialty products and technology businesses. This drove our strong fourth-quarter earnings which exceeded the increased 2025 financial guidance we provided in our third quarter earnings release,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Off...
24.02.26 - 12:03
Henry Schein Non-GAAP EPS of $1.34 beats by $0.04, revenue of $3.44B beats by $100M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.02.26 - 16:12
Henry Schein Q4 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 17:30
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy? (Zacks)
 
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
17.02.26 - 16:45
Henry Schein Q4 Earnings Preview: What′s in Store for the Stock? (Zacks)
 
HSIC gears up for Q4 results, with revenues seen rising 4.5% and strength across dental, medical and tech segments shaping expectations....
16.02.26 - 17:30
Henry Schein Stock: Analyst Estimates & Ratings (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
22.01.26 - 12:33
Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET (Business Wire)
 
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Schein website following the presentation. About Henry Schein, Inc. Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted ...
12.01.26 - 13:48
Henry Schein appoints Frederick Lowery as CEO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.01.26 - 13:06
Henry Schein Names Frederick M. Lowery as Chief Executive Officer (Business Wire)
 
Industry veteran brings more than 20 years of healthcare distribution experience and operational excellenceMELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer (“CEO”), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. Mr. Lowery brings more than two decades of healthcare expertise to Henry Schein, with a strong track record of scaling complex businesses to drive significant growth and sustained value creation. Most recently, he served as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher Scientific (NYSE: TMO), leading the Fisher Scientific distr...
29.12.25 - 20:48
One Fund Bought Up Henry Schein Stock Amid Record Quarterly Results and a New $200 Million Efficiency Plan (Fool)
 
An improving earnings profile, aggressive buybacks, and a renewed focus on margins might be changing how long-term investors think about this healthcare distributor....
23.12.25 - 22:33
Henry Schein expects to appoint next CEO by mid-January (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.12.25 - 22:09
Henry Schein Provides Update on CEO Search Process (Business Wire)
 
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) (the “Company”), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that it expects to appoint the Company's next CEO by mid-January 2026. Philip A. Laskawy, Lead Director for Henry Schein said, “We are pleased with the progress we have made in our search for Henry Schein's next CEO. The search process is nearing completion but will not be finalized before year-end. We have evaluated a pool of highly qualified candidates, and the level of interest and caliber of talent have been exceptional. We expect to make a final decision on a candidate and formal announcement regarding the appointment to the role by mid-January. In the meantime, at the Board's request Stanley Bergman will continue in his role of CEO & Chairman of Henry Schein.” Mr. Bergman commented: “The Board has engaged in a thoughtful and thorough search process. Until a successor CEO assumes the po...
18.12.25 - 07:45
DentScribe Joins Henry Schein One API Exchange as an Authorized Integration Vendor (PR Newswire)
 
DentScribe now safely and securely integrates with Dentrix to help dental practices build their best platform PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- DentScribe.ai (Suhavi AI, Inc.), an AI-powered dental documentation and clinical intelligence platform, is now an authorized......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Nahe bei Hofe, nahe bei der Hölle. - Sprichwort Deutschland
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!